← FDA Drug Approvals (Drugs@FDA)

LAMIVUDINE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: HETERO LABS LTD III · Approved 2023-10-06

Drug application

FDA Application #

ANDA091475

Application type

Abbreviated New Drug Application (Generic)

Brand name

LAMIVUDINE

Generic name

Lamivudine

Active ingredients

LAMIVUDINE

Dosage form

SOLUTION

Route

ORAL

Marketing status

Prescription

Sponsor

HETERO LABS LTD III

First approval

2023-10-06

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown